-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIDGEBIO ANNOUNCES FIRST PARTICIPANT DOSED IN ASCEND-ATTR, A PHASE 3B/4 STUDY EVALUATING THE LONG-TERM EFFECTS OF ACORAMIDIS ON DISEASE REGRESSION IN ATTR-CM

Reuters·08/26/2026 11:30:01

Please log in to view news